Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
29pct
1d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2015 · third_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; Implementation of The Prescription Drug User Fee Act (PDUFA);
Client expense: $1,240,000 · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2015 · second_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; Proposals to address chronic care coordination; Discussions on international health policy including World Health Organization resolutions;
Client expense: $930,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2015 · first_quarter · Health Issues
Discussions and proposals related to the 21st Century Cures initiative; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act H.R. 1101, Viral Hepatitis Testing Act of 2015; S. 2538, Viral Hepatitis Testing Act of 2014; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Implementation of The Prescription Drug User Fee Act (PDUFA);
Client expense: $1,870,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2015 · second_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; Proposals to address chronic care coordination; Discussions on international health policy including World Health Organization resolutions;
Client expense: $970,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2015 · second_quarter · Health Issues
H.R. 2031 Test Act, to promote innovation and collaboration of data in federal drug testing and clinical research programs.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
H.R. 2031 Test Act, to promote innovation and collaboration of data in federal drug testing and clinical research programs.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
2015 · first_quarter · Health Issues
Discussions and proposals related to the 21st Century Cures initiative; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act H.R. 1101, Viral Hepatitis Testing Act of 2015; S. 2538, Viral Hepatitis Testing Act of 2014; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Implementation of The Prescription Drug User Fee Act (PDUFA);
Client expense: $1,860,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2014 · third_quarter · Health Issues
Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Reconciliation Act of 2010; BPCIA (biosimilars); H.R. 3723, Viral Hepatitis Testing Act of 2013; Proposals to improve viral hepatitis screening and testing; H.R. 3204, Drug Quality & Security Act of 2013; S. 957, Drug Supply Chain Security Act; S. 621, Safe Prescribing Act of 2013; H. R. 1285, A bill to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug; Discussions to clarify or reform the 340B program; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2031, TEST Act
Client expense: $1,520,000 · Firm income: Not reported
2014 · fourth_quarter · Health Issues
H.R. 2031 Test Act, to promote innovation and collaboration of data in federal drug testing and approval programs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Reconciliation Act of 2010; BPCIA (biosimilars); H.R. 3723, Viral Hepatitis Testing Act of 2013; Proposals to improve viral hepatitis screening and testing; H.R. 3204, Drug Quality & Security Act of 2013; S. 957, Drug Supply Chain Security Act; S. 621, Safe Prescribing Act of 2013; H. R. 1285, A bill to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug; Discussions to clarify or reform the 340B program; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2031, TEST Act
Client expense: $1,600,000 · Firm income: Not reported
2014 · second_quarter · Health Issues
H.R. 2031, TEST Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
H.R. 2031, TEST Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
H.R. 2031, TEST Act.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · third_quarter · Health Issues
Issues related to H.R. 2031 (Test Act)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · third_quarter · Health Issues
Issues related to H.R. 2031 (Test Act)
Client expense: Not reported · Firm income: Not reported
2013 · third_quarter · Consumer Issues/Safety/Products
H.R. 2031, Trial and Experimental Studies Transparency Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)